Sage, Biogen

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests.
No deal: Sage rejects Biogen's buyout offer, scouts for strategic alternatives
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. | The company's board of directors unanimously rejected partner Biogen's $469 million buyout proposal,
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of options, such as potential strategic transactions, business combinations, or the sale of the company.
Sage Therapeutics rejects Biogen bid, starts strategic review
Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%.
Sage sues Biogen as analyst detects little interest in buyout at original offer price
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. | Sage Therapeutics has brought a lawsuit seeking a temporary restraining order against Biogen shortly after receiving an "unsolicited" offer from its neuroscience partner.
Sage Therapeutics initiates strategic review, rejects Biogen proposal
Sage Therapeutics (SAGE) announced that its board of directors has initiated a process to explore strategic alternatives for the company. The
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial instability. Learn more on SAGE stock here.
Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The company said Biogen's offer to buy all outstanding shares of Sage that it does not already own for $7.
Sage Rejects Biogen Bid, Launches Review of Alternatives
Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal significantly undervalues the biopharmaceutical company and isn't in the best interest of its shareholders.
Sage rebuffs Biogen bid to take it over
Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...
BioSpace4d
Biogen Trims Research Workforce, Higher-Dose SMA Drug Accepted for Regulatory Review
In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...
BioWorld6d
Sage lawsuit enforces standstill as board evaluates Biogen offer
A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...